The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke

Archives of Medical Science

Volumn 11, Issue 1, 2015, Pages 115-121

  Pawelczyk, Malgorzata ^a   Chmielewski, Henryk ^a   Kaczorowska, Beata ^a   Przybyła, Monika ^a   Baj, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

CD62P; HMG CoA reductase inhibitor; Hyperlipidemia; Ischemic stroke; Platelet derived microparticles; Platelets; SP selectin

Indexed keywords

BETA3 INTEGRIN; L SELECTIN; PADGEM PROTEIN; SIMVASTATIN; THROMBIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERLIPIDEMIA; MALE; PLATELET MICROPARTICLE; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 84924962244     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.49216     Document Type: Article

References (32)

1. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-4.
2. Pradeep H, Diya JB, Shashikumar S, Rajanikant GK. Oxidative stress-assassin behind the ischemic stroke. Folia Neuropathol 2012; 50: 219-30.
3. Lukasik M, Rozalski M, Luzak B, Michalak S, Kozubski W, Watala C. Platelet activation and reactivity in the convalescent phase of ischaemic stroke. Thromb Haemost 2010; 103: 644-50.
4. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-9.
5. Larsen E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59: 305-12.
6. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996; 93: 11877-82.
7. Milionis J, Elisaf MS, Mikhailidis DP. Platelet function and lipid-lowering interventions. Platelets 1999; 10: 357-67.
8. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets: a novel mechanism enhancing platelet acivity in hypercholesterolaemia. Circulation 1997; 95: 1370-5.
9. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
10. Matetzky S, Fefer P, Shenkman B, et al. Statins have an early antiplatelet effect in patients with acute myocardial infarction. Platelets 2011; 22: 103-10.
11. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 2002; 22: 1029-35.
12. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 3: 773-8.
13. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 Suppl.: 101-9.
14. Labios M, Martinez M, Gabriel F, Guiral V, Martinez E, Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res 2005; 115: 263-70.
15. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-34.
16. Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF. Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 364-6.
17. Cha JK, Jeong MH, Kim JW. Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke. J Thromb Thrombolysis 2004; 18: 39-42.
18. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90: 476-82.
19. Mazeaud MM, Driss F, Le Quan Sang KH, et al. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. Atherosclerosis 1992; 94: 201-11.
20. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49: 1035-42.
21. Ma LP, Nie DN, Hsu SX, Yin SM, Xu LZ, Nunes JV. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. J Assoc Acad Minor Phys 2002; 13: 23-6.
22. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48: 183-9.
23. Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 2003; 108: 1673-5.
24. Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJ. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999; 4: 23-6.
25. Davi G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-7.
26. Semenov AV, Romanov YA, Loktionova SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 1999; 64: 1326-35.
27. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-5.
28. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
29. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97: 13835-40.
30. Shirafuji T, Hamaguchi H, Kanda F. Measurement of platelet-derived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay. Kobe J Med Sci 2008; 54: E55-61.
31. Kuriyama N, Nagakane Y, Hosomi A, et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin Appl Thromb Hemost 2010; 16: 26-32.
32. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 2004; 18: 177-85.